Skip to main content

Table 4 Interaction effects analysis for the Week 12 and Week 52 predictor models

From: Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

 

Week 12

Week 52

Interaction effect

ASDAS-MI

ASAS40

BASDAI50

ASDAS-ID

ASDAS-MI

ASAS40

BASDAI50

ASDAS-ID

MRI*HLA-B27

0.5599

0.8460

0.1517

0.6183

0.0035*

0.0014*

0.0049*

0.0247*

Sex*MRI

0.6680

0.3600

0.6663

0.9666

0.0005*

0.9107

0.1873

0.0030*

Age*MRI

0.8676

0.5666

0.0916

0.2039

0.9140

0.8291

0.4061

0.7247

CRP*MRI

0.8584

0.4112

0.7003

0.0681

0.0626

0.7511

0.7955

0.4636

Sex*CRP

0.7179

0.3568

0.5063

0.8552

0.8904

0.7033

0.6215

0.2282

Age*CRP

0.9958

0.4325

0.0985

0.5441

0.0526

0.3986

0.9907

0.3007

  1. p-values from the final regression step are reported. *Significant interaction terms included in the final model. ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, HLA-B27 human leukocyte antigen-B27, MRI magnetic resonance imaging
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us